![News](https://firebrickpharmabucket.s3.ap-southeast-2.amazonaws.com/wp-content/uploads/2021/11/23084701/hero-banner.jpg)
Archive for January 2022
Firebrick Pharma to debut on the ASX
27 Jan 2022
Firebrick Pharma will be listed on the Australian Securities Exchange (ASX) from 12:30pm AEDT on Friday, 28 January. The Company’s flagship product, Nasodine® Nasal Spray (“Nasodine”) kills respiratory viruses and has already completed one Phase 3 clinical trial as a treatment for the common cold*. In 2022, the Company plans to complete a second, confirmatory…